Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — 34th Annual JP Morgan Healthcare Conference (January 2016)
6 slides from Jazz Pharmaceuticals's conference presentation, Jan 12, 2016
Slide 1: 34th Annual JP Morgan Healthcare Conference
© Jazz Pharmaceuticals 34th Annual JP Morgan Healthcare Conference January 11, 2016 Bruce Cozadd Chairman and Chief Executive Officer
Slide 2: Forward-Looking Statements
Forward-Looking Statements "Safe Harbor” Statement Under the Private Securities Litigation Reform Act of 1995 including, but not limited to, urrent plans, objectives, estimat which include, without limitation, uch as the ind non-US. oF at all; the ability to fir d including those the caption "Risk F
Slide 3: Growing Diversified Revenues
Growing Diversified Revenues Total Revenues! Expect to Meet Distribution of Worldwide Net Product Sales Inmillions Gulianes of $978M through September 30, 2015 $1,600 $1,320- $1,400 $1,340? . $1200 $1,473 id laice Defiteio PriallOther Erwinaze! $800 Erwinase $600 $400 Xyrem 2013 2014 2015G and conta
Slide 4: Xyrem: Continued Strong Sales
Xyrem: Continued Strong Sales 4 Expect to Meet Only FDA-approved product for both thal Seles Guidance cataplexy and EDS in patients with narcolepsy $1,000 $950-$965? + Ongoing clinical development - Phase 3 trial in pediatric patients who have narcolepsy with cataplexy, expect to complete enrollment
Slide 5: Erwinaze/Erwinase: Building for Success
Erwinaze/Erwinase: Building for Success Net Product Sales’ In millions Expect to Meet Guidane $250 Indicated Ip multi-agent $200-$2102 $200 e treatment of gi the patients with ALL who have developed itivity to E. coli-deri $150 + Support use in appropriate populations — Growth opportunity in AYA pat
Slide 6: Defitelio/defibrotide
Defitelio/defibrotide Net trod el alee Indicated in the EU for the treatment of severe ere VOD in patients undergoing HSCT therapy $100 Guidance $90 a + Launched in EU in 2014 $80 $73! ie - Focus on duration of treatment $70 — -_ . $60 + NDA Granted Priority Review by U.S. FDA $50 - PDUFA date of Ma
Jazz Pharmaceuticals — 34th Annual JP Morgan Healthcare Conference (January 2016) on 6ix